deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT05642468

Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults With Primary Sclerosing Cholangitis (PSC)

Sponsor: Albireo, an Ipsen Company

Conditions Primary Sclerosing Cholangitis
Interventions Ritivixibat
Updated 25 times since 2023 Last updated: Jul 29, 2025 Started: Jan 9, 2023 Primary completion: Jul 10, 2025 Completion: Jul 10, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05642468, this PHASE2 trial focuses on Primary Sclerosing Cholangitis and remains completed. Sponsored by Albireo, an Ipsen Company, it has been updated 25 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Jan 2024 · 4 months · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Jul 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE2

  5. May 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 20 earlier versions

  1. Apr 2025 — May 2025 [monthly]

    Recruiting PHASE2

  2. Mar 2025 — Apr 2025 [monthly]

    Recruiting PHASE2

  3. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE2

  4. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE2

  5. Dec 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  6. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  7. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  8. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  9. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  10. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  11. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  12. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  13. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE2

  14. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE2

  15. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  16. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE2

  17. Sep 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  18. Apr 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  19. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  20. Jan 2023 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Albireo, an Ipsen Company
Data source: Ipsen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations